カテゴリ： GlobalData, オーストラリア, 企業調査

Mesoblast Ltd (MSB)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Mesoblast Ltd (MSB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10046
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：78
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：オーストラリア
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Mesoblast Ltd (Mesoblast) is a regenerative medicine company, which develops regenerative cell-based products. Its pipeline product candidates include MPC-150-IM, which is under development for the treatment of chronic congestive heart failure; MSC-100-IV, for the treatment of acute graft versus host disease; MPC-06-ID, for the treatment of chronic low back pain (CLBP); and MPC-300-IV for the treatment of chronic inflammatory conditions such as biologic-refractory rheumatoid arthritis, and diabetic nephropathy. Mesoblast conducts clinical trials in areas including cardiac diseases, spinal orthopedic disorders, cancer, hematological conditions, and immune-mediated and inflammatory conditions. The company has operational presence in the US and Singapore. Mesoblast is headquartered in Melbourne, Victoria, Australia.

Mesoblast Ltd (MSB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To US$100 Million 12
Private Equity 14
Mesoblast Raises USD10 Million in Financing 14
Partnerships 16
Mesoblast Enters into Partnership with Tasly Pharma 16
Mesoblast Enters into Agreement with Cartherics 17
Mesoblast Enters into Agreement with Mallinckrodt Pharma 18
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19
Licensing Agreements 21
JCR Pharma Enters into Licensing Agreement with Mesoblast 21
Mesoblast Enters into Licensing Agreement with TiGenix 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 23
Equity Offering 24
Mesoblast Raises USD40 Million in Rights Offering of Shares 24
Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26
Mesoblast Raises USD40 Million in Private Placement of Shares 27
Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28
Mesoblast Raises USD68 Million in Public Offering of ADSs 29
Mesoblast Raises USD44.8 Million in Private Placement of Shares 31
Mesoblast Completes Private Placement Of Shares For US$174 Million 32
Acquisition 33
Teva Pharma Sells Stake in Mesoblast 33
Mesoblast Ltd – Key Competitors 34
Mesoblast Ltd – Key Employees 35
Mesoblast Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Financial Announcements 37
Aug 30, 2018: Mesoblast Reports Fourth Quarter and Full-Year 2018 Financial Results and Operational Highlights 37
May 31, 2018: Mesoblast Reports Financial Results and Operational Highlights for the Third Quarter Ended March 31, 2018 44
Feb 27, 2018: Mesoblast Announces Financial Results for the Half-Year Ended December 31, 2017 47
Aug 30, 2017: Mesoblast Operational Highlights and Financial Results for the Fourth Quarter and for the Year Ended 30 June 2017 52
Feb 26, 2017: Mesoblast Presents Corporate Update And Financial Results For The Half Year Period Ended December 31, 2016 58
Corporate Communications 62
Jul 11, 2018: Mesoblast Names Shawn Cline Tomasello As Board Director 62
Jun 19, 2018: Mesoblast Names Joseph R. Swedish As Board Director 63
May 30, 2018: Mesoblast Names Josh Muntner As New Chief Financial Officer 64
Product News 65
10/29/2018: JCR to initiate development of TEMCELL HS Inj. (JR-031EB) for the indication of epidermolysis bullosa 65
Product Approvals 66
Mar 07, 2017: FDA Grants Fast Track Designation For Mesoblast’s Cell Therapy In Children With Acute Graft Versus Host Disease 66
Clinical Trials 67
Sep 20, 2018: Children treated with remestemcel-l continue to have strong survival outcomes at six months in mesoblast’s phase 3 trial for acute graft versus host disease 67
Jun 21, 2018: Key Day 100 Survival Outcomes of Phase 3 Trial for Acute Graft Versus Host Disease Presented at 2018 ISSCR Annual Meeting 68
May 08, 2018: Mesoblast Phase 3 Trial Results for Acute Graft Versus Host Disease Presented at 2018 International Society for Cell and Gene Therapy Annual Meeting 69
Feb 22, 2018: Primary Endpoint Successfully Achieved in Mesoblast’s Phase 3 Cell Therapy Trial for Acute Graft Versus Host Disease 70
Dec 20, 2017: Mesoblasts Phase 3 Trial In Children With Acute Graft Versus Host Disease Completes Enrollment 71
Sep 25, 2017: Mesoblast Presents Update on lead product candidate MSC-100-IV at Global Healthcare Conferences 72
Aug 16, 2017: Positive Trial Results of Mesoblast Cell Therapy in Post-traumatic Osteoarthritis Published in Arthritis Research & Therapy 73
Apr 10, 2017: Successful Interim Analysis of Efficacy Endpoint In Mesoblasts Phase 3 Trial for Chronic Heart Failure 74
Apr 03, 2017: FDA Clears Heart Disease Trial At Harvard’s Boston Children’s Hospital Using Mesoblast’s Cell Therapy In Children With Congenital Heart Disease 75
Mar 31, 2017: Independent Data Monitoring Committee Initiates Process for Interim Analysis of Mesoblasts Phase 3 Chronic Heart Failure Trial 76
Other Significant Developments 77
Dec 07, 2017: Mesoblast Named Global Technology Leader in Cell Therapy Industry 77
Appendix 78
Methodology 78
About GlobalData 78
Contact Us 78
Disclaimer 78

List of Tables
Mesoblast Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mesoblast Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mesoblast Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mesoblast Acquires Mesenchymal Stem Cell Portfolio From Osiris Therapeutics For Up To US$100 Million 12
Mesoblast Raises USD10 Million in Financing 14
Mesoblast Enters into Partnership with Tasly Pharma 16
Mesoblast Enters into Agreement with Cartherics 17
Mesoblast Enters into Agreement with Mallinckrodt Pharma 18
Mesoblast Enters Into Co-Development Agreement With Intrexon And Ziopharm Oncology 19
JCR Pharma Enters into Licensing Agreement with Mesoblast 21
Mesoblast Enters into Licensing Agreement with TiGenix 22
Mesoblast Enters into Licensing Agreement with Harvard Medical School 23
Mesoblast Raises USD40 Million in Rights Offering of Shares 24
Mesoblast Plans to Raise up to USD180 Million in Public Offering of American Depositary Shares 26
Mesoblast Raises USD40 Million in Private Placement of Shares 27
Mesoblast to Raise up to USD45 Million in Private Placement of Shares 28
Mesoblast Raises USD68 Million in Public Offering of ADSs 29
Mesoblast Raises USD44.8 Million in Private Placement of Shares 31
Mesoblast Completes Private Placement Of Shares For US$174 Million 32
Teva Pharma Sells Stake in Mesoblast 33
Mesoblast Ltd, Key Competitors 34
Mesoblast Ltd, Key Employees 35
Mesoblast Ltd, Other Locations 36
Mesoblast Ltd, Subsidiaries 36

List of Figures
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mesoblast Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mesoblast Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Mesoblast Ltd (MSB)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Plug Power Inc (PLUG)：企業の財務・戦略的SWOT分析
    Summary Plug Power Inc (Plug Power) is an alternative energy company that designs and develops fuel cell structures. The company’s products comprise gendrive, genkey, material handling products, gensure, genfuel and genfuel for stationary markets products. Its material handling products comprise out …
  • OncoSec Medical Inc (ONCS)：医療機器：M&Aディール及び事業提携情報
    Summary OncoSec Medical Inc (OncoSec) is a biotechnology company that offers services to stimulate body’s immune system and attack cancer. It’s lead candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through i …
  • Unibail-Rodamco-Westfield Se：企業の戦略・SWOT・財務分析
    Unibail-Rodamco-Westfield Se - Strategy, SWOT and Corporate Finance Report Summary Unibail-Rodamco-Westfield Se - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Tulip Star Hotels Limited：企業の戦略・SWOT・財務分析
    Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary Tulip Star Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ITT Inc.：企業の戦略・SWOT・財務情報
    ITT Inc. - Strategy, SWOT and Corporate Finance Report Summary ITT Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Evolving Systems Inc (EVOL)：企業の財務・戦略的SWOT分析
    Summary Evolving Systems Inc (Evolving Systems) is a technology company that provides development, delivering and supporting technologies and vendor independent software solutions. The company offers software solutions such as real-time lifecycle marketing, dynamic sim allocation, tertio service act …
  • Tianjin Zhonghuan Semiconductor Co. Ltd. (002129)：企業の財務・戦略的SWOT分析
    Tianjin Zhonghuan Semiconductor Co. Ltd. (002129) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Samson Oil & Gas Ltd (SSN)：石油・ガス：M&Aディール及び事業提携情報
    Summary Samson Oil & Gas Limited (Samson) is engaged in the acquisition, exploitation, exploration and development of oil and natural gas properties in the US. It is also engaged in producing natural gas liquids. The company’s projects include Foreman Butte project, which is located in Williston Bas …
  • Verde Science Inc-石油・ガス分野：企業M&A・提携分析
    Summary Verde Science Inc (Verde Science), formerly Rango Energy Inc is a medical technology company that offers bioprocess solutions. The company offers research and development services with expertise in bioprocess technology, molecular virology and immunology, nanotechnology, pharmacology and med …
  • Elders Limited：企業の戦略・SWOT・財務情報
    Elders Limited - Strategy, SWOT and Corporate Finance Report Summary Elders Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Natera Inc (NTRA)：企業の財務・戦略的SWOT分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers Panorama, a non-invasive prenatal screening test that analyzes baby's DNA through a simple blood dra …
  • RTI Surgical Inc (RTIX)-医療機器分野：企業M&A・提携分析
    Summary RTI Surgical Inc (RTI), formerly RTI Biologics Inc is a surgical implant company that offers biologic, metal and synthetic implants. The company’s products include spine implants, surgical specialties, sports medicine implants, cardiothoracic and orthobiologics. It offers spine implants such …
  • Herstal SA：企業の戦略・SWOT・財務情報
    Herstal SA - Strategy, SWOT and Corporate Finance Report Summary Herstal SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • NuVista Energy Ltd (NVA)：企業の財務・戦略的SWOT分析
    Summary NuVista Energy Ltd (NuVista) is an oil and gas company that offers exploration, development and production of oil and natural gas reserves. The company conducts its operations in Western Canadian Sedimentary Basin which is located in West Central Alberta and Northeast British Columbia areas …
  • Quanta Services Inc (PWR)：企業の財務・戦略的SWOT分析
    Quanta Services Inc (PWR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Cypark Resources Berhad (CYPARK)：企業の財務・戦略的SWOT分析
    Summary Cypark Resources Berhad (CRB) is a clean technology company that offers environmental engineering services. The company offers engineering and technology services on transforming dump sites to an economic and environmental boon. Its services include environmental remediation, integrated wast …
  • McEwen Mining Inc.：企業の戦略・SWOT・財務情報
    McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report Summary McEwen Mining Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Euskaltel SA (EKT)：企業の財務・戦略的SWOT分析
    Euskaltel SA (EKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Currence Holding B.V.：企業の戦略・SWOT・財務分析
    Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report Summary Currence Holding B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Providence Resources plc (PZQA)：企業の財務・戦略的SWOT分析
    Summary Providence Resources Plc (Providence Resource) is an upstream oil and gas exploration and development company that explores and develops hydrocarbon assets. The company's areas of operations include Northern Porcupine basin, Southern Porcupine basin, Goban Spur basin, Saint George's basin an …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆